Evidence map›Paper›PMID 38093832›Full record

ReviewACS pharmacology & translational science2023

Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools.

Akbar Hasanzadeh, Arefeh Ebadati, Lida Dastanpour, Amir R Aref, Parham Sahandi Zangabad, Alireza Kalbasi, Xiaofeng Dai, Geeta Mehta, Amir Ghasemi, Yousef Fatahi and 3 more

Open access · greenAbstract readReview
In one paragraph

Review in ACS pharmacology & translational science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 12 citations in OpenAlex.

  1. The role of stem cells in precision medicine: next-generation cancer treatment.Journal of the Egyptian National Cancer Institute · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 5 countries.

Akbar HasanzadehCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran 14535, Iran.
Arefeh EbadatiCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran 14535, Iran.
Lida DastanpourCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran 14535, Iran.
Amir R ArefDepartment of Medical Oncology and Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts 02115, United States.
Parham Sahandi ZangabadMonash Institute of Pharmaceutical Sciences, Department of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Melbourne, Victoria 3052, Australia.
Alireza KalbasiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States.
Xiaofeng DaiSchool of Biotechnology, Jiangnan University, Wuxi 214122, China.
Geeta MehtaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States.ORCID https://orcid.org/0000-0001-5967-6425
Amir GhasemiDepartment of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran 14535, Iran.
Yousef FatahiNanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 14166, Iran.ORCID https://orcid.org/0000-0003-0374-2141
Suhasini JoshiChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Michael R HamblinLaser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein 2028, South Africa.
Mahdi KarimiCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran 14535, Iran.ORCID https://orcid.org/0000-0002-9358-9613
Iran University of Medical Sciences · IRDana-Farber Cancer Institute · USIslamic Azad University, Tehran · IRJiangnan University · CNMemorial Sloan Kettering Cancer Center · USMonash University · AUSharif University of Technology · IRUniversal Scientific Education and Research Network · IRUniversity of Michigan · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Personalized medicine is a new approach toward safer and even cheaper treatments with minimal side effects and toxicity. Planning a therapy based on individual properties causes an effective result in a patient's treatment, especially in a complex disease such as cancer. The benefits of personalized medicine include not only early diagnosis with high accuracy but also a more appropriate and effective therapeutic approach based on the unique clinical, genetic, and epigenetic features and biomarker profiles of a specific patient's disease. In order to achieve personalized cancer therapy, understanding cancer biology plays an important role. One of the crucial applications of personalized medicine that has gained consideration more recently due to its capability in developing disease therapy is related to the field of stem cells. We review various applications of pluripotent, somatic, and cancer stem cells in personalized medicine, including targeted cancer therapy, cancer modeling, diagnostics, and drug screening. CRISPR-Cas gene-editing technology is then discussed as a state-of-the-art biotechnological advance with substantial impacts on medical and therapeutic applications. As part of this section, the role of CRISPR-Cas genome editing in recent cancer studies is reviewed as a further example of personalized medicine application.

Identifiers

PMID38093832
PMCPMC10714436
OpenAlexW4388671747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.